Grant Street Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Grant Street Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4	Closed	-$2K	–	230
2020 Q4	$2K	Buy	+4	New	+$2.16K	﹤0.01%	216

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grant Street Asset Management's REGN Position: Q1 2021 in Review

Grant Street Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 4 shares — an estimated $2K sold.

Grant Street Asset Management first reported a position in REGN in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Grant Street Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Grant Street Asset Management sold 4 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $2K.
Grant Street Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Grant Street Asset Management's Regeneron Pharmaceuticals position peaked at $2K in Q4 2020.
924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Grant Street Asset Management's 13F filing for Q1 2021, filed 4 May 2021.